Literature DB >> 2536836

Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.

G D Westrop1, K A Wareham, D M Evans, G Dunn, P D Minor, D I Magrath, F Taffs, S Marsden, M A Skinner, G C Schild.   

Abstract

The poliovirus type 3 Sabin oral poliovirus vaccine strain P3/Leon/12a1b differs in nucleotide sequence from its neurovirulent progenitor P3/Leon/37 by just 10 point mutations. The contribution of each mutation to the attenuation phenotype of the vaccine strain was determined by the construction of a series of recombinant viruses from infectious cDNA clones. The neurovirulence testing of recombinant viruses indicated that the attenuation phenotype is determined by just two point mutations: a C to U in the noncoding region at position 472 and a C to U at nucleotide 2034 which results in a serine-to-phenylalanine amino acid substitution in the structural protein VP3.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536836      PMCID: PMC247831     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee.

Authors:  P D Minor; A John; M Ferguson; J P Icenogle
Journal:  J Gen Virol       Date:  1986-04       Impact factor: 3.891

2.  In vitro phenotypic markers of a poliovirus recombinant constructed from infectious cDNA clones of the neurovirulent Mahoney strain and the attenuated Sabin 1 strain.

Authors:  M Kohara; T Omata; A Kameda; B L Semler; H Itoh; E Wimmer; A Nomoto
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

3.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

4.  Genetic analysis of the attenuation phenotype of poliovirus type 1.

Authors:  T Omata; M Kohara; S Kuge; T Komatsu; S Abe; B L Semler; A Kameda; H Itoh; M Arita; E Wimmer
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

5.  Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.

Authors:  A J Cann; G Stanway; P J Hughes; P D Minor; D M Evans; G C Schild; J W Almond
Journal:  Nucleic Acids Res       Date:  1984-10-25       Impact factor: 16.971

6.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

7.  Molecular variation of type 1 vaccine-related and wild polioviruses during replication in humans.

Authors:  B K Nottay; O M Kew; M H Hatch; J T Heyward; J F Obijeski
Journal:  Virology       Date:  1981-01-30       Impact factor: 3.616

8.  The carrier state in muscular dystrophy of the Duchenne type.

Authors:  A T Milhorat; L Goldstone
Journal:  JAMA       Date:  1965-10-11       Impact factor: 56.272

9.  Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.

Authors:  D M Evans; G Dunn; P D Minor; G C Schild; A J Cann; G Stanway; J W Almond; K Currey; J V Maizel
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

10.  Comparative biochemical studies of type 3 poliovirus.

Authors:  P D Minor
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

View more
  91 in total

1.  Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus.

Authors:  T Kanno; D Mackay; T Inoue; G Wilsden; M Yamakawa; R Yamazoe; S Yamaguchi; J Shirai; P Kitching; Y Murakami
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Neurovirulence of type 1 polioviruses isolated from sewage in Japan.

Authors:  Hitoshi Horie; Hiromu Yoshida; Kumiko Matsuura; Miwako Miyazawa; Yoshihiro Ota; Takashi Nakayama; Yutaka Doi; So Hashizume
Journal:  Appl Environ Microbiol       Date:  2002-01       Impact factor: 4.792

3.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA.

Authors:  N Percy; W S Barclay; M Sullivan; J W Almond
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating.

Authors:  J M Tatem; C Weeks-Levy; A Georgiu; S J DiMichele; E J Gorgacz; V R Racaniello; F R Cano; S J Mento
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  A single base deletion in the 5' noncoding region of Theiler's virus attenuates neurovirulence.

Authors:  A E Pritchard; M A Calenoff; S Simpson; K Jensen; H L Lipton
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

7.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

8.  Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses.

Authors:  J J Holland; J C de la Torre; D K Clarke; E Duarte
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

9.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  An attenuating mutation in the 2A protease of swine vesicular disease virus, a picornavirus, regulates cap- and internal ribosome entry site-dependent protein synthesis.

Authors:  Y Sakoda; N Ross-Smith; T Inoue; G J Belsham
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.